Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2019-08-20 | CRTX | Cortexyme, Inc. | Epiq Capital Group, LLC | IA/Managing Member 10% owner | P - Purchase | $25.35 | +4,965 | 8,497,683 | 0% | +$125,863 | |||||
| D | 2019-08-19 | NSTG | Nanostring Technologies Inc | Ghesquiere David W. | SVP, Corporate, Business Dev | S - Sale+OE | $28.23 | -18,421 | 51,822 | -26% | -$520,113 | |||||
| AD | 2019-06-05 | NSTG | Nanostring Technologies Inc | Ghesquiere David W. | SVP, Corporate, Business Dev | S - Sale+OE | $29.41 | -6,954 | 51,822 | -12% | -$204,493 | |||||
2019-08-20 | INMB | Inmune Bio, Inc. | Moss David J | CFO, Treasurer, Secretary, 10% | P - Purchase | $5.65 | +3,000 | 1,223,417 | 0% | +$16,950 | ||||||
2019-08-20 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $5.99 | +2,000 | 1,540,933 | 0% | +$11,987 | ||||||
2019-08-19 | ALEC | Alector, Inc. | King Robert | Chief Development Officer | S - Sale | $15.00 | -7,500 | 529,817 | -1% | -$112,500 | ||||||
| M | 2019-08-19 | ALEC | Alector, Inc. | Paul Robert | Chief Medical Officer | S - Sale | $16.00 | -2,000 | 321,719 | -1% | -$32,000 | |||||
| D | 2019-08-19 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $37.55 | -15,000 | 246,000 | -6% | -$563,243 | |||||
| D | 2019-08-20 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Strategy Officer | S - Sale+OE | $124.00 | -500 | 40,921 | -1% | -$62,000 | |||||
2019-08-19 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale | $19.04 | -3,000 | 8,513 | -26% | -$57,120 | ||||||
2019-08-19 | EDIT | Editas Medicine, Inc. | Collins Cynthia | CEO | S - Sale | $25.83 | -5,193 | 11,373 | -31% | -$134,135 | ||||||
| M | 2019-08-16 | AERI | Aerie Pharmaceuticals Inc | Foresite Capital Management Ii, LLC | 10% | P - Purchase | $23.88 | +153,847 | 2,204,324 | +8% | +$3,673,289 | |||||
| DM | 2019-08-16 | TWST | Twist Bioscience Corp | Thorburn James M | CFO | S - Sale+OE | $29.81 | -10,000 | 39,002 | -20% | -$298,107 | |||||
2019-08-12 | MGTX | Meiragtx Holdings Plc | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $23.50 | +425,531 | 6,433,277 | +7% | +$9,999,979 | ||||||
2019-08-16 | CASI | Casi Pharmaceuticals, Inc. | He Wei-Wu | CEO, 10% | P - Purchase | $3.20 | +20,000 | 6,226,623 | 0% | +$64,000 | ||||||
2019-08-19 | ASRT | Assertio Therapeutics, Inc | Higgins Arthur J | Dir, Pres, CEO | P - Purchase | $1.61 | +25,000 | 265,879 | +10% | +$40,243 | ||||||
2019-08-19 | GILD | Gilead Sciences Inc | Pletcher Brett A | EVP, GC, Corp Sec | S - Sale | $64.35 | -608 | 27,198 | -2% | -$39,123 | ||||||
2019-08-16 | ONVO | Organovo Holdings, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale | $0.29 | -22,230 | 138,484 | -14% | -$6,431 | ||||||
2019-08-15 | ALEC | Alector, Inc. | Paul Robert | Chief Medical Officer | S - Sale | $14.19 | -10,000 | 323,719 | -3% | -$141,900 | ||||||
| M | 2019-08-16 | CRTX | Cortexyme, Inc. | Epiq Capital Group, LLC | IA/Managing Member 10% owner | P - Purchase | $26.46 | +2,800 | 2,829,596 | 0% | +$74,100 | |||||
| M | 2019-08-14 | JNCE | Jounce Therapeutics, Inc. | Cole Hugh M | Chief Business Officer | S - Sale | $3.99 | -2,336 | 36,214 | -6% | -$9,330 | |||||
| M | 2019-08-14 | JNCE | Jounce Therapeutics, Inc. | Trehu Elizabeth | Chief Medical Officer | S - Sale | $3.99 | -2,336 | 59,189 | -4% | -$9,330 | |||||
| M | 2019-08-14 | JNCE | Jounce Therapeutics, Inc. | Drapkin Kimberlee C | CFO, Treasurer | S - Sale | $3.99 | -2,336 | 47,014 | -5% | -$9,330 | |||||
| D | 2019-08-14 | CHRS | Coherus Biosciences, Inc. | Anicetti Vincent R | COO | S - Sale+OE | $19.00 | -2,500 | 19,310 | -11% | -$47,500 | |||||
| D | 2019-08-14 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale+OE | $16.62 | -17,000 | 123,182 | -12% | -$282,547 | |||||
| M | 2019-08-13 | LCTX | Lineage Cell Therapeutics, Inc. | Broadwood Partners, L.P. | Dir, 10% | P - Purchase | $0.98 | +24,553 | 68,073,666 | 0% | +$24,045 | |||||
2019-08-14 | CASI | Casi Pharmaceuticals, Inc. | He Wei-Wu | CEO, 10% | P - Purchase | $3.17 | +160,000 | 6,206,623 | +3% | +$507,200 | ||||||
| D | 2019-08-13 | LCTX | Lineage Cell Therapeutics, Inc. | Leavitt Chase C. | GC, Secretary | P - Purchase | $1.02 | +5,000 | 5,000 | New | +$5,100 | |||||
2019-08-13 | LCTX | Lineage Cell Therapeutics, Inc. | Roberts Brandi | CFO, SVP, Finance | P - Purchase | $1.01 | +5,000 | 5,000 | New | +$5,050 | ||||||
2019-08-13 | LCTX | Lineage Cell Therapeutics, Inc. | Culley Brian M | Pres, CEO | P - Purchase | $1.01 | +10,000 | 84,531 | +13% | +$10,100 | ||||||
| M | 2019-08-12 | AERI | Aerie Pharmaceuticals Inc | Foresite Capital Management Ii, LLC | 10% | P - Purchase | $24.73 | +539,555 | 2,050,477 | +36% | +$13,341,170 | |||||
| D | 2019-08-12 | BOLD | Audentes Therapeutics, Inc. | Patterson Matthew R | CEO | S - Sale+OE | $34.04 | -20,000 | 287,182 | -7% | -$680,835 | |||||
| DM | 2019-08-12 | DYAI | Dyadic International Inc | Tchelet Ronen | VP of Research, Bus. Dvlpmt | S - Sale+OE | $5.74 | -10,000 | 0 | -100% | -$57,389 | |||||
| AD | 2019-05-13 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale+OE | $26.59 | -50,000 | 49,905 | -50% | -$1,329,421 | |||||
| D | 2019-08-12 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale+OE | $24.84 | -40,000 | 49,905 | -44% | -$993,706 | |||||
| D | 2019-08-13 | NSTG | Nanostring Technologies Inc | Malloy Kirk | Dir | S - Sale+OE | $25.05 | -1,000 | 0 | -100% | -$25,051 | |||||
| D | 2019-08-13 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale+OE | $11.93 | -2,778 | 512,797 | -1% | -$33,142 | |||||
2019-08-12 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale | $11.64 | -533 | 69,290 | -1% | -$6,204 | ||||||
2019-08-12 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale | $11.64 | -114 | 7,390 | -2% | -$1,327 | ||||||
2019-08-12 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale | $11.64 | -354 | 5,015 | -7% | -$4,121 | ||||||
2019-08-12 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale | $11.64 | -533 | 100,819 | -1% | -$6,204 | ||||||
2019-08-12 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale | $11.74 | -1,773 | 509,403 | 0% | -$20,815 | ||||||
| A | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale | $11.67 | -608 | 69,823 | -1% | -$7,095 | |||||
| A | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale | $11.67 | -226 | 7,504 | -3% | -$2,637 | |||||
| A | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale | $11.67 | -215 | 5,369 | -4% | -$2,509 | |||||
| A | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale | $11.67 | -636 | 101,352 | -1% | -$7,422 | |||||
2019-08-12 | ASRT | Assertio Therapeutics, Inc | Higgins Arthur J | Dir, Pres, CEO | P - Purchase | $1.54 | +50,000 | 240,879 | +26% | +$76,900 | ||||||
2019-08-09 | INMB | Inmune Bio, Inc. | Tesi Raymond Joseph | Pres, CEO, 10% | P - Purchase | $7.03 | +2,000 | 1,538,933 | 0% | +$14,058 | ||||||
2019-08-09 | XLRN | Acceleron Pharma Inc | Veness Adam M | VP, GC, Sec. | S - Sale | $45.00 | -3,268 | 16,925 | -16% | -$147,060 | ||||||
| D | 2019-08-08 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $124.03 | -950 | 30,092 | -3% | -$117,824 | |||||
2019-08-09 | TCON | Tracon Pharmaceuticals, Inc. | Theuer Charles | Pres, CEO | P - Purchase | $0.45 | +50,000 | 173,565 | +40% | +$22,500 | ||||||
2019-08-07 | ALEC | Alector, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $17.90 | -650,000 | 3,171,804 | -17% | -$11,635,000 | ||||||
2019-08-07 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COO, Secretary | S - Sale | $18.81 | -7,500 | 634,631 | -1% | -$141,075 | ||||||
| D | 2019-08-08 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $76.52 | -20,149 | 746,294 | -3% | -$1,541,827 | |||||
| D | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale+OE | $11.72 | -2,601 | 511,176 | -1% | -$30,484 | |||||
| D | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale+OE | $11.82 | -626 | 101,362 | -1% | -$7,399 | |||||
| D | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale+OE | $11.82 | -210 | 5,374 | -4% | -$2,482 | |||||
| D | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale+OE | $11.82 | -221 | 7,509 | -3% | -$2,612 | |||||
| D | 2019-08-08 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale+OE | $11.82 | -598 | 69,833 | -1% | -$7,068 | |||||
| D | 2019-08-07 | TECH | Bio-Techne Corp | Baumgartner Robert V | Dir | P - Purchase | $191.06 | +500 | 8,726 | +6% | +$95,530 | |||||
| DM | 2019-08-06 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | CEO | S - Sale+OE | $95.31 | -80,000 | 417,597 | -16% | -$7,624,975 | |||||
2019-08-07 | AMGN | Amgen Inc | Williams R Sanders | Dir | S - Sale | $183.04 | -425 | 5,838 | -7% | -$77,792 | ||||||
| D | 2019-08-07 | AMGN | Amgen Inc | Sugar Ronald D | Dir | S - Sale+OE | $183.04 | -2,000 | 14,336 | -12% | -$366,080 | |||||
2019-08-06 | SGEN | Seattle Genetics Inc /wa | Liu Jean I | GC, EVP, Leg Affairs | S - Sale | $75.00 | -3,716 | 70,633 | -5% | -$278,700 | ||||||
| D | 2019-08-06 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $116.08 | -5,060 | 31,616 | -14% | -$587,389 | |||||
| D | 2019-08-06 | NSTG | Nanostring Technologies Inc | Bailey K Thomas | CFO | S - Sale+OE | $25.24 | -35,625 | 0 | -100% | -$899,026 | |||||
2019-08-07 | BIEI | Premier Biomedical Inc | Felder Mitchell S | COB, 10% | P - Purchase | $0.01 | +1,000,000 | 1,328,031 | +305% | +$7,300 | ||||||
2019-08-06 | ADAP | Adaptimmune Therapeutics Plc | Amado Rafael | Pres, R, D | S - Sale | $2.06 | -11,043 | 17,237 | -39% | -$22,749 | ||||||
| D | 2019-08-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $116.93 | -850 | 30,342 | -3% | -$99,393 | |||||
| D | 2019-08-02 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir, 10% | P - Purchase | $6.00 | +166,666 | 1,003,083 | +20% | +$999,996 | |||||
2019-08-03 | HALO | Halozyme Therapeutics, Inc. | Chondros Dimitrios | SVP, Chief Medical Officer | S - Sale | $16.70 | -1,328 | 38,584 | -3% | -$22,178 | ||||||
| M | 2019-08-01 | AXLA | Axcella Health Inc. | Epstein David R | Dir | P - Purchase | $7.00 | +6,941 | 38,293 | +22% | +$48,619 | |||||
| M | 2019-07-31 | FATE | Fate Therapeutics Inc | Nashat Amir | Dir | S - Sale | $22.53 | -62,005 | 11,034 | -85% | -$1,397,066 | |||||
2019-07-30 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale | $92.07 | -10,000 | 235,697 | -4% | -$920,686 | ||||||
| D | 2019-07-30 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $92.13 | -15,831 | 19,961 | -44% | -$1,458,569 | |||||
| D | 2019-07-30 | NBIX | Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | CHIEF RESEARCH OFFICER | S - Sale+OE | $92.92 | -60,000 | 108,408 | -36% | -$5,575,438 | |||||
| D | 2019-07-30 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $92.77 | -44,356 | 141,976 | -24% | -$4,114,858 | |||||
| M | 2019-07-26 | FATE | Fate Therapeutics Inc | Nashat Amir | Dir | S - Sale | $22.51 | -118,333 | 11,635 | -91% | -$2,663,115 | |||||
| DM | 2019-07-26 | ALLO | Allogene Therapeutics, Inc. | Moore Alison | Chief Technical Officer | S - Sale+OE | $29.44 | -48,827 | 65,373 | -43% | -$1,437,603 | |||||
2019-07-25 | SLDB | Solid Biosciences Inc. | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $4.65 | +2,822,581 | 6,749,803 | +72% | +$13,125,002 | ||||||
| D | 2019-07-23 | GILD | Gilead Sciences Inc | Pletcher Brett A | EVP, GC, Corp Sec | S - Sale+OE | $65.07 | -7,200 | 27,198 | -21% | -$468,504 | |||||
| M | 2019-07-23 | FATE | Fate Therapeutics Inc | Nashat Amir | Dir | S - Sale | $22.51 | -81,899 | 12,781 | -87% | -$1,843,151 | |||||
| D | 2019-07-19 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $49.49 | -15,000 | 246,000 | -6% | -$742,311 | |||||
2019-07-19 | AVRO | Avrobio, Inc. | Atlas Venture Fund X, L.P. | 10% | P - Purchase | $18.50 | +810,811 | 5,567,289 | +17% | +$15,000,004 | ||||||
2019-07-19 | AVRO | Avrobio, Inc. | Booth Bruce | Dir | P - Purchase | $18.50 | +810,811 | 5,567,289 | +17% | +$15,000,004 | ||||||
| M | 2019-07-18 | FATE | Fate Therapeutics Inc | Nashat Amir | Dir | S - Sale | $22.52 | -71,166 | 13,574 | -84% | -$1,602,506 | |||||
| DM | 2019-07-18 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale+OE | $50.03 | -5,000 | 3,058 | -62% | -$250,147 | |||||
| D | 2019-07-17 | SGEN | Seattle Genetics Inc /wa | Gryska David W | Dir | S - Sale+OE | $75.00 | -5,000 | 48,013 | -9% | -$375,000 | |||||
2019-07-17 | AXLA | Axcella Health Inc. | Epstein David R | Dir | P - Purchase | $7.55 | +1,000 | 31,352 | +3% | +$7,550 | ||||||
| D | 2019-07-15 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $87.50 | -30,680 | 141,976 | -18% | -$2,684,506 | |||||
2019-07-15 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale | $87.44 | -5,835 | 14,910 | -28% | -$510,201 | ||||||
2019-07-16 | XLRN | Acceleron Pharma Inc | Veness Adam M | VP, GC, Sec. | S - Sale | $40.71 | -538 | 20,193 | -3% | -$21,902 | ||||||
| D | 2019-07-15 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale+OE | $19.68 | -17,000 | 123,182 | -12% | -$334,579 | |||||
| D | 2019-07-15 | RUBY | Rubius Therapeutics, Inc. | Langer Robert | Dir | S - Sale+OE | $14.94 | -7,500 | 0 | -100% | -$112,049 | |||||
| D | 2019-07-15 | CHRS | Coherus Biosciences, Inc. | Anicetti Vincent R | COO | S - Sale+OE | $19.20 | -2,500 | 19,310 | -11% | -$48,000 | |||||
| D | 2019-07-10 | TECH | Bio-Techne Corp | Kummeth Charles R. | CEO | S - Sale+OE | $213.12 | -16,969 | 92,176 | -16% | -$3,616,428 | |||||
| DM | 2019-07-10 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $87.63 | -7,220 | 141,976 | -5% | -$632,717 | |||||
| DM | 2019-07-10 | CRSP | Crispr Therapeutics AG | Klein Lawrence Otto | Chief Business Officer | S - Sale+OE | $50.02 | -20,000 | 20,000 | -50% | -$1,000,353 | |||||
2019-07-10 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale | $50.00 | -50,000 | 848,007 | -6% | -$2,500,065 | ||||||
| M | 2019-07-08 | AXLA | Axcella Health Inc. | Epstein David R | Dir | P - Purchase | $8.24 | +5,796 | 30,352 | +24% | +$47,743 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |